Opinion|Videos|November 17, 2026

Beyond One Best HIV Regimen: Shared Decisions and Bictegravir/Lenacapavir

With treatment moving away from a single preferred regimen, shared decision-making tools and a new NRTI-free combination give pharmacists more ways to match therapy to the individual.

In "Beyond One Best HIV Regimen: Shared Decisions and Bictegravir/Lenacapavir," our experts turn to the new data reshaping how regimens are matched to individual patients.

Dr. Astle describes how he helps patients navigate a growing menu of treatment choices. He builds pro and con tables and uses visual handouts to show what each option entails. He avoids assumptions and does not lead with what he thinks is best. Instead, he compares consistent attributes across medications so patients can make the choice themselves. Dr. Madison agrees that the era of a single best regimen is over. She likens the current landscape to a buffet of options. Treatment must be tailored to lived experience, which changes over time as jobs and insurance coverage shift.

Dr. Durham then interprets the ARTISTRY-1 and ARTISTRY-2 trials of bictegravir/lenacapavir. The combination showed noninferior efficacy to bictegravir/emtricitabine/tenofovir alafenamide, including in patients with prior NRTI resistance. He is curious where future DHHS updates will place it. Because neither component is an NRTI, it is a reasonable option for patients with NRTI resistance. It is approved for regimen simplification, which is an appropriate current use. Patients with resistance to other classes are less likely to carry both integrase and capsid resistance. That makes the combination a potential option for people with multidrug-resistant HIV. It has not been studied as first-line therapy. Still, Dr. Durham suggests it may eventually become a recommended initial option as clinical experience grows.

Dr. Madison highlights a practical advantage. The combination is considered the smallest HIV pill currently available. Many oral HIV tablets remain relatively large and difficult to swallow. For patients with swallowing challenges, a smaller tablet may be a meaningful benefit. The panel agrees that pill size is an underappreciated factor when weighing oral regimens, particularly for patients who have struggled with larger single-tablet options in the past.

Our next episode, "Twice-Yearly HIV Therapy: Lenacapavir Plus Broadly Neutralizing Antibodies," looks ahead to a potential twice-yearly regimen and what it would take to make it routine.

Funding supported by Gilead. Content independently developed by Pharmacy Times.


Related to this article